Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics

February 24, 2023 By Cade Hildreth (CEO) Leave a Comment

Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.

The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.

[Read more…]

Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors

February 15, 2023 By Cade Hildreth (CEO) Leave a Comment

FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]

Do You Know The 5 Types Of Stem Cells?

February 14, 2023 By Cade Hildreth (CEO) 5 Comments

As you start to learn about stem cells, one of the most common questions to have is, “What types of stem cells exist?” There is not an agreed-upon number of stem cell types, because one can classify stem cells either by differentiation potential (what they can turn into) or by origin (from where they are sourced).

This post is dedicated to explaining the five types of stem cells, based on differentiation potential. [Read more…]

Immunotherapy company iPSirius appoints Dr. Stephen Sullivan as Chief Operating Officer

February 10, 2023 By Cade Hildreth (CEO) Leave a Comment

iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells

Paris, France, 10^th February 2023 – iPSirius, a pre-clinical biotech company in the immuno-oncology field, is pleased to announce the appointment of a new COO, Dr. Stephen Sullivan. Dr. Sullivan, previously the program manager at the Global Alliance for iPSC therapies, is a pluripotent stem cell manufacturing expert. He will oversee the day-to-day operations of the company and the first in-human trials for the company’snovel therapeutic, IPVAC. [Read more…]

Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2023

February 4, 2023 By Cade Hildreth (CEO) 1 Comment

Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprogramming and turning on the expression of specific pluripotency genes. This reprogramming can be achieved using different techniques with varying efficiencies. [Read more…]

iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells

BioInformant's World-Class Clients